EAU–ESTRO–SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

Published on Apr 1, 2017in European Urology17.947
· DOI :10.1016/J.EURURO.2016.08.003
Nicolas Mottet40
Estimated H-index: 40
Joaquim Bellmunt87
Estimated H-index: 87
(Harvard University)
+ 19 AuthorsPhilip Cornford27
Estimated H-index: 27
Abstract Objective To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on screening, diagnosis, and local treatment with curative intent of clinically localised prostate cancer (PCa). Evidence acquisition The working panel performed a literature review of the new data (2013–2015). The guidelines were updated and the levels of evidence and/or grades of recommendation were added based on a systematic review of the evidence. Evidence synthesis BRCA2 mutations have been added as risk factors for early and aggressive disease. In addition to the Gleason score, the five-tier 2014 International Society of Urological Pathology grading system should now be provided. Systematic screening is still not recommended. Instead, an individual risk-adapted strategy following a detailed discussion and taking into account the patient's wishes and life expectancy must be considered. An early prostate-specific antigen test, the use of a risk calculator, or one of the promising biomarker tools are being investigated and might be able to limit the overdetection of insignificant PCa. Breaking the link between diagnosis and treatment may lower the overtreatment risk. Multiparametric magnetic resonance imaging using standardised reporting cannot replace systematic biopsy, but robustly nested within the diagnostic work-up, it has a key role in local staging. Active surveillance always needs to be discussed with very low-risk patients. The place of surgery in high-risk disease and the role of lymph node dissection have been clarified, as well as the management of node-positive patients. Radiation therapy using dose-escalated intensity-modulated technology is a key treatment modality with recent improvement in the outcome based on increased doses as well as combination with hormonal treatment. Moderate hypofractionation is safe and effective, but longer-term data are still lacking. Brachytherapy represents an effective way to increase the delivered dose. Focal therapy remains experimental while cryosurgery and HIFU are still lacking long-term convincing results. Conclusions The knowledge in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. The 2016 EAU-ESTRO-SIOG Guidelines on PCa summarise the most recent findings and advice for the use in clinical practice. These are the first PCa guidelines endorsed by the European Society for Radiotherapy and Oncology and the International Society of Geriatric Oncology and reflect the multidisciplinary nature of PCa management. A full version is available from the EAU office and online (http://uroweb.org/guideline/prostate-cancer/). Patient summary The 2016 EAU-STRO-IOG Prostate Cancer (PCa) Guidelines present updated information on the diagnosis, and treatment of clinically localised prostate cancer. In Northern and Western Europe, the number of men diagnosed with PCa has been on the rise. This may be due to an increase in opportunistic screening, but other factors may also be involved (eg, diet, sexual behaviour, low exposure to ultraviolet radiation). We propose that men who are potential candidates for screening should be engaged in a discussion with their clinician (also involving their families and caregivers) so that an informed decision may be made as part of an individualised risk-adapted approach.
Figures & Tables
📖 Papers frequently viewed together
1,343 Citations
404 Citations
468 Citations
#1W. Robert Lee (Duke University)H-Index: 39
#2James J. Dignam (U of C: University of Chicago)H-Index: 61
Last. Howard M. Sandler (Cedars-Sinai Medical Center)H-Index: 96
view all 19 authors...
PurposeConventional radiotherapy (C-RT) treatment schedules for patients with prostate cancer typically require 40 to 45 treatments that take place from > 8 to 9 weeks. Preclinical and clinical research suggest that hypofractionation—fewer treatments but at a higher dose per treatment—may produce similar outcomes. This trial was designed to assess whether the efficacy of a hypofractionated radiotherapy (H-RT) treatment schedule is no worse than a C-RT schedule in men with low-risk prostate cance...
258 CitationsSource
#1Luca Incrocci (EUR: Erasmus University Rotterdam)H-Index: 38
#2Ruud C. Wortel (EUR: Erasmus University Rotterdam)H-Index: 8
Last. Floris J. Pos (NKI-AVL: Netherlands Cancer Institute)H-Index: 27
view all 11 authors...
Summary Background Studies have reported a low α/β ratio for prostate cancer, suggesting that hypofractionation could enhance the biological tumour dose without increasing genitourinary and gastrointestinal toxicity. In the multicentre phase 3, HYpofractionated irradiation for PROstate cancer (HYPRO) trial, hypofractionated radiotherapy was compared with conventionally fractionated radiotherapy for treatment of prostate cancer. We have previously reported acute and late incidence of genitourinar...
212 CitationsSource
#1Maarten de Rooij (Radboud University Nijmegen)H-Index: 12
#2E.H.J. Hamoen (Radboud University Nijmegen)H-Index: 7
Last. Maroeska M. Rovers (Radboud University Nijmegen)H-Index: 46
view all 5 authors...
Abstract Context Correct assessment of tumour stage is crucial for prostate cancer (PCa) management. Objective To assess the diagnostic accuracy of magnetic resonance imaging (MRI) for local PCa staging and explore the influence of different imaging protocols. Evidence acquisition We searched the PubMed, Embase, and Cochrane databases from 2000 up to August 2014. We included studies that used MRI for detection of extracapsular extension (ECE; T3a), seminal vesicle invasion (SVI; T3b), or overall...
270 CitationsSource
#1David P. Dearnaley (ICR: Institute of Cancer Research)H-Index: 108
#2Isabel Syndikus (Clatterbridge Cancer Centre NHS Foundation Trust)H-Index: 27
Last. Emma Hall (ICR: Institute of Cancer Research)H-Index: 57
view all 29 authors...
Summary Background Prostate cancer might have high radiation-fraction sensitivity that would give a therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy and side-effects of a randomised trial comparing conventional and hypofractionated radiotherapy after 5 years follow-up. Methods CHHiP is a randomised, phase 3, non-inferiority trial that recruited men with localised prostate cancer (pT1b–T3aN0M0). Patients were randomly assigned (1:1:1) to conve...
459 CitationsSource
#1Nicola Fossati (UniSR: Vita-Salute San Raffaele University)H-Index: 36
#2R. Jeffrey Karnes (Mayo Clinic)H-Index: 70
Last. Alberto Briganti (UniSR: Vita-Salute San Raffaele University)H-Index: 96
view all 17 authors...
Abstract Background Early salvage radiation therapy (eSRT) represents a treatment option for patients who experience a prostate-specific antigen (PSA) rise after radical prostatectomy (RP); however, the optimal PSA level for eSRT administration is still unclear. Objective To test the impact of PSA level on cancer control after eSRT according to pathologic tumour characteristics. Design, setting, and participants The study included 716 node-negative patients with undetectable postoperative PSA wh...
64 CitationsSource
#1Christopher J.D. Wallis (U of T: University of Toronto)H-Index: 24
#2Alyson L. Mahar (Sunnybrook Health Sciences Centre)H-Index: 23
Last. Robert K. Nam (Sunnybrook Health Sciences Centre)H-Index: 54
view all 9 authors...
Objective To determine the association between exposure to radiotherapy for the treatment of prostate cancer and subsequent second malignancies (second primary cancers). Design Systematic review and meta-analysis of observational studies. Data sources Medline and Embase up to 6 April 2015 with no restrictions on year or language. Study selection Comparative studies assessing the risk of second malignancies in patients exposed or unexposed to radiotherapy in the course of treatment for prostate c...
101 CitationsSource
#1Nicholas D. James (Warw.: University of Warwick)H-Index: 66
#2Melissa R. Spears (UCL: University College London)H-Index: 12
Last. Matthew R. Sydes (UCL: University College London)H-Index: 70
view all 23 authors...
MPORTANCE: The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. Furthermore, no clinical trial has assessed the role of RT in patients with node-positive (N+) M0 disease. The STAMPEDE Trial includes such individuals, allowing an exploratory multivariate analysis of the impact of radical RT. OBJECTIVE: To describe survival and the impact on fa...
92 CitationsSource
#1John S. BanerjiH-Index: 5
#2Erika WolffH-Index: 9
Last. John M. CormanH-Index: 21
view all 6 authors...
Purpose: We determined whether the characteristics of patients undergoing prostate needle biopsies and prostate needle biopsy results changed after the U.S. Preventive Services Task Force recommendation in 2012 against prostate specific antigen based screening for prostate cancer for men of any age.Materials and Methods: A prospective database of patients undergoing prostate needle biopsies at Virginia Mason from 2004 to 2014 was reviewed. Welch’s t-test and chi-square tests were used to compare...
56 CitationsSource
#1Jelle O. BarentszH-Index: 92
#2Jeffrey C. Weinreb (Yale University)H-Index: 73
Last. Peter L. Choyke (NIH: National Institutes of Health)H-Index: 140
view all 12 authors...
Department of Radiology and Nuclear Medicine Radboudumc, Nijmegen, The Netherlands; Yale School of Medicine, New Haven, CT, USA; University of Cincinnati, Cincinnati, OH, USA; Harvard University, Boston, MA, USA; University Hospital of Bern, Bern, Switzerland; AdMeTech Foundation, Boston, MA, USA; g Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood, Middlesex, UK; University of California, Los Angeles, CA, USA; i Johns Hopkins University, Baltimore, MD, USA; University of Toronto,...
314 CitationsSource
#1Eduard Baco (University of Oslo)H-Index: 16
#2Erik Rud (University of Oslo)H-Index: 10
Last. Osamu Ukimura (SC: University of Southern California)H-Index: 52
view all 8 authors...
Abstract Background Prostate biopsy guided by computer-assisted fusion of magnetic resonance imaging (MRI) and transrectal ultrasound (TRUS) images (MRI group) has not yet been compared with 12-core random biopsy (RB; control group) in a randomized controlled trial (RCT). Objective To compare the rate of detection of clinically significant prostate cancer (csPCa) between the two groups. Design, setting, and participants This RCT included 175 biopsy-naive patients with suspicion for prostate canc...
147 CitationsSource
Cited By1813
#1Semra Özdemir (Çanakkale Onsekiz Mart University)H-Index: 1
#2Ahmet Reşit Ersay (Çanakkale Onsekiz Mart University)H-Index: 7
view all 4 authors...
The early detection of bone metastases is very important in prostate cancer follow-up. This study aimed to compare conventional tumor markers, namely free prostate-specific antigen (free PSA), total prostate-specific antigen (total PSA), free PSA/total PSA ratio, alkaline phosphatase (ALP) values, Gleason scores and 99 m Tc-MDP bone scintigraphy findings in the prediction of bone metastases in prostate cancer. In total, 175 patients with prostate cancer who underwent whole-body bone scintigraphy...
#1Elin Axén (Sahlgrenska University Hospital)H-Index: 5
#2Rebecka Arnsrud Godtman (Sahlgrenska University Hospital)H-Index: 8
Last. Peter Wiklund (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 54
view all 0 authors...
Abstract null null Background null Reports on possible benefits for continence with nerve-sparing (NS) radical prostatectomy have expanded the indications beyond preservation of erectile function. It is unclear whether NS surgery affects oncological outcomes. null null null Objective null To determine whether the degree of NS during radical prostatectomy influences oncological outcomes. null null null Design, setting, and participants null Of 4003 patients enrolled in a prospective, controlled t...
#1Amogh Hiremath (Case Western Reserve University)H-Index: 2
#2Rakesh Shiradkar (Case Western Reserve University)H-Index: 6
Last. Anant Madabhushi (VA: United States Department of Veterans Affairs)H-Index: 66
view all 0 authors...
BACKGROUND Biparametric MRI (comprising T2-weighted MRI and apparent diffusion coefficient maps) is increasingly being used to characterise prostate cancer. Although previous studies have combined Prostate Imaging-Reporting & Data System (PI-RADS)-based MRI findings with routinely available clinical variables and with deep learning-based imaging predictors, respectively, for prostate cancer risk stratification, none have combined all three. We aimed to construct an integrated nomogram (referred ...
Abstract null Background null Radiotherapy to the prostate (RTp) prolongs survival for patients with low-volume, newly diagnosed metastatic prostate cancer (ndmPC). null Objective null to evaluate whether cytoreductive radical prostatectomy (cRP) is equally beneficial as RTp in low-volume ndmPC. null Design, setting, and participants null A multicenter prospective registry was established in 2014 to observe patients with ndmPC. Eligible patients were offered cRP or RTp. For this study we selecte...
#1Joseph Kabunda (Sefako Makgatho Health Sciences University)
#2Lerato Gabela (UKZN: University of KwaZulu-Natal)
view all 6 authors...
Purpose This prospective study was aimed at assessing the ability of 99mTc-PSMA scan to detect bone metastases in prostate cancer (PCa) against 99mTc-MDP scan as a standard and assess the correlation of these modalities in PCa staging of bone involvement. Patients and methods Forty-one patients (41) with histologically confirmed PCa were scanned using both methods. Planar imaging was performed with additional regional SPECT/CT 3 to 4 hours posttracer injection. Scans were reported as positive, n...
#1V. Groen (UU: Utrecht University)H-Index: 1
#2Nicolaas P.A. Zuithoff (UU: Utrecht University)H-Index: 28
Last. Karin Haustermans (Katholieke Universiteit Leuven)H-Index: 74
view all 0 authors...
BACKGROUND AND PURPOSE The phase III FLAME trial (NCT01168479) showed an increase in five-year biochemical disease-free survival, with no significant increase in toxicity when adding a focal boost to external beam radiotherapy (EBRT) for localized prostate cancer [Kerkmeijer et al. JCO 2021]. The aim of this study was to investigate the association between delivered radiation dose to the anorectum and gastrointestinal (GI) toxicity (grade ≥2). MATERIAL AND METHODS All patients in the FLAME trial...
#1Lucie-Marie Scailteux (University of Rennes)H-Index: 5
#2Valérian Capelle (University of Rennes)
Last. Anthony Chapron (University of Rennes)H-Index: 5
view all 0 authors...
OBJECTIVE The aim of the study was to determine the trend of first blood PSA test prescription in France between 2011 and 2017, based on the assumption that prostate cancer (PCa) screening is expected to decline over the years. METHOD Using a representative sample of the French population from the French Health Insurance database, we identified 50-52-year-old men without PCa and without any blood PSA test in the five years before 2011, 2014 and 2017 (January 1 to December 31 of each year). For e...
#1T. Spitznagel (UZH: University of Zurich)H-Index: 1
#2Jost von Hardenberg (Heidelberg University)H-Index: 9
Last. Daniel Eberli (UZH: University of Zurich)H-Index: 31
view all 0 authors...
Abstract null null Objectives null To report feasibility and outcome of salvage robotic-assisted laparoscopic radical prostatectomy (S-RALP) after focal therapy using high-intensity focused ultrasound (HIFU) treatment compared to primary robotic-assisted laparoscopic radical prostatectomy (pRALP). null null null Methods null In this bicentric trial patients undergoing S-RALP for detection of WHO2016/ISUP Grade Group 2 or 3 prostate cancer were previously treated in prospective focal HIFU trials....
#1Ingrid Jenny Guldvik (Oslo University Hospital)H-Index: 9
Last. Wolfgang Lilleby (Oslo University Hospital)H-Index: 18
view all 0 authors...
De novo metastatic or recurrence of prostate cancer (PC) remains life-threatening. Circulating tumor cells (CTCs) are noninvasive biomarkers and provide unique information that could enable tailored treatment. This study evaluated the impact of CTCs in PC patients eligible for peptide vaccine therapy. Twenty-seven patients were tested for CTCs with the CellCollector® device (Detector CANCER01(DC01)) during short-term androgen deprivation therapy (ADT) before cancer vaccine treatment (cohort 1) o...